Breast Cancer Research Semi-postal Stamps

Breast Cancer Research Semi-postal Stamps are subject to special limitations and conditions:
    a. Breast Cancer Research Semi-postal Stamps provide a means for customers to make contributions toward breast cancer research. Breast Cancer Research Semi-postal Stamps are offered for sale for a limited time as provided under 39 U.S.C. 414.
    b. The price of the Breast Cancer Research Semi-postal Stamp is 40 cents. The postage value of the Breast Cancer Research Semi-postal Stamp is the First-Class Mail Non automation Single-Piece first-ounce letter rate in R100.1.2 that is in effect at the time of purchase. The difference between the purchase price and the First-Class Mail Non automation Single-Piece first-ounce letter rate in effect at the time of purchase constitutes a contribution to breast cancer research, and cannot be used to pay postage. Additional postage must be affixed to pieces weighing in excess of one ounce, pieces subject to the nonstandard surcharge, or pieces for which special services have been elected. The postage value of Breast Cancer Research Semi-postal Stamps is fixed according to the First-Class Mail Non automation Single-Piece first-ounce letter rate in effect at the time of purchase; the postage value of Breast Cancer Research Semi-postal Stamps purchased before any subsequent change in the First-Class Mail Non automation Single-Piece first-ounce letter rate is unaffected by any subsequent change in that rate.
    c. Contributions to breast cancer research made through purchase of Breast Cancer Research stamps are not refundable. The postage value of Breast Cancer Research stamps for purposes of exchange or conversion under P014 is determined by the First-Class Mail Non automation Single-
Piece rate in effect at the time of purchase

 

Bush’s Trillion $ LIES About SS

WASHINGTON, Oct. 26 /PRNewswire/ — The Susan G. Komen Breast Cancer Foundation, credited as the nation’s leading catalyst in the fight against breast cancer, released today a non-partisan comparison of key health care proposals announced by Vice President Gore and Governor Bush in their quest for the Presidency.  The comparison is based on answers to a health care questionnaire designed by the Komen Foundation, to which both campaigns responded.  The Foundation hopes that the side-by-side analysis of the candidates’ varying proposals will assist voters in comparing and contrasting the approach each would take to important health care issues impacting women and families.

As a leader in the healthcare arena, the Susan G. Komen Breast Cancer Foundation has consistently promoted a broad range of issues impacting women and families.  The Komen Foundation, a bipartisan non-profit organization, works to educate women throughout the United States about the importance of these issues in their daily lives.

The Komen Foundation is an international organization with 114 domestic Affiliates in 45 states and the District of Columbia, as well as three Affiliates in Germany, Greece and Italy.  Since its inception, the Komen Foundation has raised more than $300 million to support breast cancer research, education, and screening and treatment programs.  These programs include cutting-edge basic, clinical and translational breast cancer research, and innovative outreach programs in local communities to assist the medically underserved.  The Susan G. Komen Breast Cancer Foundation is a nonpartisan charitable organization that does not endorse or oppose any candidate for public office

PROSTATE CANCER RESEARCH FUNDING

Mr. President, I would like to call the attention of my colleagues to a national health epidemic that kills 40,000 American men every year and strikes hundreds of thousands more each year–prostate cancer. I am concerned about this disease and its impact on American men, particularly its disproportionate impact on African-American men.
  For too long prostate cancer has been a silent killer. Too little has been known about it. Too little was said about it. Too little has been done about it. Fortunately, in recent years many prominent national figures like Senator Bob Dole, General Norman Schwarzkopf, Arnold Palmer, Sidney Poitier, Andy Grove, and Harry Belafonte have come forward to discuss their personal battles with prostate cancer. The admirable leadership of these men and others has helped educate the country about the importance of screening and early diagnosis of prostate cancer, and the need for all of us to do more to fight this disease.
  Mr. President, prostate cancer is the most commonly occurring non- skin cancer in the United States. In 1997, more than 200,000 men were diagnosed with prostate cancer and 41,800 died of the disease. Every three minutes a new case of prostate cancer is diagnosed and every 13 minutes someone dies from the disease. While it is often thought to be an older man’s disease, younger men are increasingly diagnosed with prostate cancer. In fact, about 20 percent of prostate cancers are now occurring in men between the ages of 40 and 60.
  Although prostate cancer accounts for approximately 20 percent of all new non-skin cancers, it receives less than four percent of federal cancer research funding. In 1996, approximately the same number of lives were lost due to prostate cancer breast cancer and AIDS. In 1997, however, while prostate cancer deaths continued to rise, deaths due to breast cancer and AIDS declined. Nevertheless, the federal commitment to prostate cancer research has not even kept pace with these other
priorities.
  Clearly, I am not advocating reduced funding for breast cancer or AIDS research programs. I have been one of the major champions of breast cancer and AIDS research funding. Rather, I use these comparisons to make the point that much more must be done to address the prostate cancer epidemic as well. How can we face the hundreds of thousands of men and their families who are daily affected by prostate cancer knowing, for instance, that more money was spent to make the movie Titanic–more than $200 million–than was spent in 1997 by the federal government for prostate cancer research–only $120 million?
  The possibility and the fear of developing prostate cancer are common to all men. One in five American men will develop prostate cancer during his lifetime. As frightening as that statistic may be for the general population, it is even more pointed in the African-American community. African-American men have a prostate cancer incidence more than 30 percent higher than for any other ethnic groups in this country and the highest in the world.
  The prostate cancer mortality rate for African-American men is more than twice that of white American men. Researchers do not yet know why this is true and do not yet have answers to these and the many other questions about prostate cancer. For example, it is not clear which prostate cancer patients will benefit from traditional treatments, like surgery or radiation. The economic status of many African-American men, and limited access to medical counseling further complicated treatment decisions.
  Those who are devoted to relieving the burden of prostate cancer in the African-American community, including scientists, health care providers, national organizations, community leaders, and survivors alike, are united in their desire to find answers to these questions. I am particularly pleased with the leadership of many national organizations in informing the country about the impact of prostate cancer in the African-American community. In November of last year, the American Cancer Society, the National Cancer Institute, and the Centers for Disease Control and Prevention sponsored A Leadership Council on Prostate Cancer in the African-American Community. In cooperation with the Intercultural Cancer Council, the National Black Leadership Initiative on Cancer, the National Prostate Cancer Coalition and the 100 Black Men of America, the Leadership Conference proposed a blueprint for action that aims to solve the problem of prostate cancer in the African-American community.
  These private organizations–and many others–are working very hard at the community and national levels to see that the prostate cancer epidemic is addressed. That a letter that 29 organizations representing the African-American community sent to Congress in May laying out a research funding agenda to attack this problem be printed in the Record.

2000CRE1167C BREAST CANCER RESEARCH STAMP REAUTHORIZATION ACT OF 2000

Mr. LAZIO. Mr. Speaker, I rise to introduce the bill entitled the Breast Cancer Research Stamps Reauthorization Act of 2000.
Breast cancer is the most commonly diagnosed cancer among women in the United States. More than 2 million American women are currently living with the disease, 1 million of whom have yet to be diagnosed. This year alone, 182,800 women will be diagnosed with breast cancer. Over 40,000 of them will lose their battle with this killer.
Breast cancer has taken an awful toll on the people of my home state. New York has the second-highest breast cancer mortality rate in the country. Between 1980 and 1994, the incidence of breast cancer in New York increased nearly 18 percent. Enactment of this bill will go a long way toward helping our effort to increase funding for breast cancer research. Only through the help of continued cancer research have more and more people become cancer survivors in recent years.
Since the issuance of the Breast Cancer Research stamp in the summer of 1998, 164 million Breast Cancer Research stamps have been sold rising over $12 million for breast cancer research. The stamp provides a convenient avenue for participation in the battle against this horrible disease. Unfortunately, without congressional intervention, the stamp will expire on July 28, 2000. Valuable research funds, as well as a mechanism to heighten public awareness of this horrible disease, will be lost.
This bill, The Breast Cancer Research Stamp Reauthorization Act of 2000 would extend the sale of the Breast Cancer Research stamp for an additional two years. The stamp would continue to cost 40 cents and sell as a first class stamp. The additional funds that are raised will go directly to breast cancer research at the National Institutes of Health and the Department of Defense.
I am pleased to report that this reauthorization bill has tremendous support throughout the health community. Supporters of the Breast Cancer Stamp Reauthorization Act of 2000 include the American Cancer Society, the American Medical Association, the Y-Me National Breast Cancer Organization, Leadership America, the National Association of Women’s Health, the American Cancer League, the American College of Surgeons, Friends of Cancer Research, and many others.
A Breast Cancer Research Stamp remains just as necessary today as it was when this authority was signed into law two years ago. According to the American Association for Cancer Research, 8 million people are alive today as a result of cancer research. To say that every dollar we continue to raise will save lives, can only underscore the importance of this legislation.
I urge my colleagues to join me in enacting this important legislation.

 

Postdoctoral Position in Signal Transduction and Cancer

Immediately available in Department of Pathology, Yale University School of Medicine. The applicant must have strong background in molecular biology or immunology or cancer biology. The commitment to basic science research is required.  The applicants with the potential to obtain a fellowship from NIH or other foundations are prefered.

Project will involve studies of signal transduction from cytokine receptors to transcription factor STAT and their possible roles in cancer development.

Background and our Research Interest:

A variety of protein ligands (such as hormones and cytokines) induce activation of protein tyrosine kinases (PTK) and affect gene expression.   Our laboratory working on a recently established signaling pathway involving direct activation of cytoplasmic transcription factors by tyrosine kinases. A direct signaling model of signal transduction has been proposed (Fu, 1992). In this model, the transcription factors (termed STAT) are directly activated by a membrane receptor-associated tyrosine kinase(s) through their   SH2 (Src homology region 2) domains. These activated transcription factors then translocate to the nucleus to join a nuclear protein to form an active transcriptional complex, inducing expression of specific functional proteins.  Most recently, studies from our lab and other laboratories have also demonstrated that Interferons, EGF, PDGF, CSF-1, IL-2, IL-3, IL-4, IL-5, IL-6, and IL-10 etc., all use this direct pathway to control nuclear transcriptional events (reviewed in Darnell et al., 1994). A fundamental question in cancer research is whether and how these signaling pathways are involved abnormal cell growth and transformation of normal cells.  Our current research is aiming to expand our understanding of the signal transduction of cytokines, especially the functions of STAT to the field of cancer immunology which includes STAT function in  cancer development  and in the general cellular immune responses.

 

BREAST CANCER RESEARCH — Buy Postage Stamps!!

As you may be aware, the US Postal Service recently released its new “Fund the Cure” stamp to help fund breast cancer research. The stamp was designed by Ethel Kessler of Bethesda, Maryland.  It is important that we take a stand against this disease that kills and maims so many of our mothers, sisters, and friends.

Instead of the normal $.33 for a stamp, this one costs $.40.  The additional $.07 will go to breast cancer research.  A “normal” book costs $6.60.  This one is only $8.00. It takes a few minutes in line at the Post Office and means so much.  If all stamps are sold, it will raise an additional $16,000,000 for this vital research. Many of us know women and their families whose lives are turned upside-down by breast cancer.  It takes so little to do so much in this drive.

While I have no objection to the issuance of semi-postal stamps to fund breast cancer research, I think that is is a self-deception.  The cure, if that is the correct term, is most likely to come from fundamental biological research pursued by biologists that are not quite so goal oriented to meet their sponsors’ desires.

During Nixon’s presidency, a “war” on cancer was started.  More than 20 years later the biggest steps to fight cancer have come from mainline biological research into subjects like genetics, angiogenesis, drug action, etc.  While the money spent was not wasted, it was not used efficiently.  The goal oriented research tries to tackle problems for which the science is not available.  It does sound good, however, to the desperate suffering from the disease.  In a sense, the science for a cure is not here yet.

It should be obvious to this group that arthritis has not been cured although fundamental knowledge has greatly increased.  The result has been better treatments.  Realize however, that study of autoimmune disease and immunity in general, for example, is what will pay dividends for BOTH arthritis and breast cancer therapy.

We also see another useless war in action.  The war on drugs.  It too is a means to divert resources into the pockets of special interests while doing little to solve our nation’s drug problems. I just had to get on my soap box.  It irks me to see people following panaceas that will only prove to be a disappointment.  The main advantage, not to be underated, is that it makes people feel emotionally better.

 

 

Raising Money for Breast Cancer Research

SACRAMENTO, CA —As a skilled and successful surgeon, Dr. Ernie Bodai has used his medical expertise to teach, invent surgical tools, start a business, and lecture. However, in January, he decided to work for “pennies” in very different realms…social activism and political lobbying. A thousand breast cancer operations has convinced Bodai, Chief of Surgery, at Kaiser Permanente, Sacramento, CA, that much larger- scale research is needed.  ”We just haven’t progressed in the diagnosis and treatment of breast cancer,” Bodai exclaims.

The Cure Breast Cancer (CBC) campaign would raise money in an innovative way.  Bodai is lobbying the Postal Service and Congress to issue a voluntary 33 cent postage stamp. If purchased, the extra penny would go to breast cancer research at the National Institutes of Health (This is not the recently issued Breast Cancer Awareness Stamp which does not raise any additional funds for cancer research.).  Dr. Bodai said, “60 billion dollars of 32 cent stamps are issued annually. If half of them were 33 cent stamps, that could raise as much as 300 million dollars.”

Although this goal hasn’t been achieved yet, Bodai is confident because of early successes. His compassion, civic mindedness, and talent have already impressed Congress.  In just nine months, Bodai and his volunteers have promoted and lobbied all the way to getting the breast cancer postage stamp introduced into both Houses of Congress, with ninety Representatives and four Senators on the bandwagon thus far.

Bodai works tirelessly for public support. With the help of supporters such as Mercy Davidchik, a breast cancer survivor, the surgeon conducts a “grass roots” campaign to get signatures on petitions to Congressional leaders and endorsements from all types of local, state, and national organizations.

“We have obtained many letters from city and county officials to Congress, and we just received the endorsement of the California State Senate,” said Davidchik, a former patient of Dr. Bodai.  Currently, we are conducting a nationwide letter writing campaign to get support and publicity from large health-related and  civic groups,” she added. National organizations already supporting the idea include the American Cancer Society and American Medical Association.

Opponents have raised concerns about costs of administering such a stamp, but Dr. Bodai’s plan calls for corporate donations from companies profiting from this disease to help defray the costs of designing, printing, and publicizing the stamp.The Postal Service, with its new computerized stamp accounting system, would issue the stamps and the extra funds would be transferred directly to the National Institutes of Health.”We want to prove that you still can get something for a penny,” said Davidchik. “This could raise hundreds of millions of dollars without any significant financial burden on individual citizens.”

While CBCtm has gathered much support, further help in the U.S. Congress is needed. Volunteers across the country need to circulate petitions or write individual letters to their U.S.

 

Psilocybin And Cancer Research

The Research &Education Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety,
depression, and physical pain.

In order to participate, you must:

Have stage IV cancer and anxiety.
Be between the ages of 18 – 65.
Not have cancer that affects the central nervous system or brain function.
Have no history of major psychiatric disorder.
Have no kidney disease, abnormal liver functions, diabetes, epilepsy, or cardiovascular disease, including hypertension.
Not be taking insulin, oral hypoglycemic, anti-seizure, high blood pressure, or heart medications. If you qualify and choose to participate, you will spend two nights at the hospital for medication administration. Receive psilocybin, a novel psychoactive medication. Get an MRI scan of the brain if you have not had one recently.

Prostate cancer research 10years behind breast cancer research

Santa Rosa Memorial Hospital has been selected to take part in what doctors said is a promising 10-year national study on whether vitamin supplements can help prevent prostate cancer, the second leading cause of death for men.

The research project is funded as part of a National Cancer Institute study that involves tracking the health of 32,000 men, some of whom will be taking supplements of Vitamin E and selenium, a sulfur-like chemical that occurs naturally in fresh produce. It will be the largest ever study of prostate cancer prevention. “This is the way we make progress against cancer,” said Tish Murphy, a nurse and research program manager.

The cancer research center is currently conducting about 60 other clinical trials involving lung, breast, colon and lymphoma cancer. However, officials say this one is intriguing because prostate cancer is regarded as one of the most preventable and treatable of all cancers. “In prostate cancer research, we are 10 years behind the level where we are today in breast cancer research,” said Dr. Wayne Keiser, an oncologist and principal investigator of program research.

After lung cancer, prostate cancer is the leading cause of death among American men. Cancer of the prostate gland, which controls the flow of urine, has been found to be more common in men over 55, in families with histories of prostate cancer, among blacks, and among heavy smokers and drinkers.

About 200,000 new cases of prostate cancer are diagnosed every year, and more than 30,000 prostate cancer deaths are reported annually. There is increasing evidence from less extensive clinical trials that Vitamin E and selenium reduce the incidence of prostate cancer. In addition, an increasing number of urologists are prescribing supplements such as Vitamin E, selenium and saw palmetto to men concerned about prostate health. The cancer research program run by Santa Rosa Memorial is looking for about 40 men to participate in the study. The cancer center advertised last October for clinical trial participants and received about 100 inquiries. However, only 11 turned out to be eligible because many were excluded for various reasons, including the fact that they were already taking the dietary supplements and did not wish to stop.

Keiser said the proliferation of health information – particularly that available over the Internet – has made it more difficult for research programs like theirs to recruit participants. Clinical trials involve long-term commitments to taking prescribed dosages, including placebos, and medical information often supersedes trial results. “Doctors and patients want to have the best possible things, but there are times that things turn out to be the opposite of what we think,” Keiser said. “The truth is that we don’t know that Vitamin E or selenium work.”

Keiser cited the example of the weight-loss supplement ephedra, which was in common use long before clinical trials deemed it to be harmful. The Memorial Hospital cancer center on Round Barn Boulevard operates about 60 clinical trials and a dozen pharmaceutical trials under contract with the Redwood Regional Medical Group. The group of 30 oncologists and radiologists perform much of the cancer treatment in Sonoma, Marin, Mendocino and Lake Counties. Ann Lowry, cancer center research coordinator, said the program intends to place new advertisements for participants and seek help from local doctors.

 

NOT RELATED… IMPORTANT CANCER RESEARCH

The American Cancer Society will donate 3 cents for cancer research to everyone who receives this letter. Or should that read: “cancer research ON everyone.

BTW, so-called science has done a miserable job “curing” cancers. Most of the “improvements” in cure rates are due to the fact that they are now calling things “cancer” that were never considered cancer before. The ACS is almost complete bs. (I used to work for them — it’s a social club, and they’re ignoramuses.) Ditto the AMA (Twenty-three years ago I was given 6-10 years to live. What do they say now? “Well, you must not have had it, then.” Ah, but that wouldn’t have stopped you guys from gutting me like a fish, radiating me and dumping chemo toxins through me, would it? Yeah, if I’d followed their treatment, I would have been lucky to live 6-10 years.) In a very short time, 20th Century medicine will be written off as the dark ages.

Your best treatment at the present time, following the advice of Baron von Munchausen, is “no doctors”. Get literate. Know your body. Take every nutritional supplement on earth and try to be sure your body has everything it needs, get plenty of rest, and your body will do a better job healing itself than these arrogant clowns in medicine ever could.